Comparison Overview

VIVENDA SPA

VS

Roche

VIVENDA SPA

Via Francesco Antolisei Rome, Lazio 00173, IT
Last Update: 2025-03-16 (UTC)
Between 900 and 1000

Excellent

None

NAICS: 541
NAICS Definition:
Employees: 2-10
Subsidiaries: 0
12-month incidents
0
Known data breaches
0
Attack type number
0

Roche

Grenzacherstrasse, None, Switzerland ๐Ÿ‡จ๐Ÿ‡ญ , None, CH, 4070
Last Update: 2025-05-27 (UTC)

Excellent

Between 900 and 1000

Roche is a global pioneer in pharmaceuticals and diagnostics focused on advancing science to improve peopleโ€™s lives. The combined strengths of pharmaceuticals and diagnostics under one roof have made Roche the leader in personalised healthcare โ€“ a strategy that aims to fit the right treatment to each patient in the best way possible. Roche is the worldโ€™s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. Founded in 1896, Roche continues to search for better ways to prevent, diagnose and treat diseases and make a sustainable contribution to society. The company also aims to improve patient access to medical innovations by working with all relevant stakeholders. Thirty medicines developed by Roche are included in the World Health Organization Model Lists of Essential Medicines, among them life-saving antibiotics, antimalarials and cancer medicines. Roche has been recognised as the Group Leader in sustainability within the Pharmaceuticals, Biotechnology & Life Sciences Industry ten years in a row by the Dow Jones Sustainability Indices (DJSI). For more information, please visit https://careers.roche.com Read our community guidelines here: https://www.roche.com/some-guidelines.htm #Roche #Biotechnology #Pharmaceuticals #Diagnostics #Healthcare #PersonalisedHealthcare #GreatPlaceToWork #Innovation

NAICS: 541714
NAICS Definition: Research and Development in Biotechnology (except Nanobiotechnology)
Employees: 99,293
Subsidiaries: 51
12-month incidents
0
Known data breaches
0
Attack type number
0

Compliance Badges Comparison

Security & Compliance Standards Overview

https://images.rankiteo.com/companyimages/vivenda-spa.jpeg
VIVENDA SPA
โ€”
ISO 27001
Not verified
โ€”
SOC 2
Not verified
โ€”
GDPR
No public badge
โ€”
PCI DSS
No public badge
https://images.rankiteo.com/companyimages/roche.jpeg
Roche
โ€”
ISO 27001
Not verified
โ€”
SOC 2
Not verified
โ€”
GDPR
No public badge
โ€”
PCI DSS
No public badge
Compliance Summary
VIVENDA SPA
100%
Compliance Rate
0/4 Standards Verified
Roche
0%
Compliance Rate
0/4 Standards Verified

Benchmark & Cyber Underwriting Signals

Incidents vs Biotechnology Research Industry Average (This Year)

No incidents recorded for VIVENDA SPA in 2025.

Incidents vs Biotechnology Research Industry Average (This Year)

No incidents recorded for Roche in 2025.

Incident History โ€” VIVENDA SPA (X = Date, Y = Severity)

VIVENDA SPA cyber incidents detection timeline including parent company and subsidiaries

Incident History โ€” Roche (X = Date, Y = Severity)

Roche cyber incidents detection timeline including parent company and subsidiaries

Notable Incidents

Last 3 Security & Risk Events by Company

https://images.rankiteo.com/companyimages/vivenda-spa.jpeg
VIVENDA SPA
Incidents

No Incident

https://images.rankiteo.com/companyimages/roche.jpeg
Roche
Incidents

No Incident

FAQ

Both VIVENDA SPA company and Roche company demonstrate a comparable AI risk posture, with strong governance and monitoring frameworks in place.

Historically, Roche company has disclosed a higher number of cyber incidents compared to VIVENDA SPA company.

In the current year, Roche company and VIVENDA SPA company have not reported any cyber incidents.

Neither Roche company nor VIVENDA SPA company has reported experiencing a ransomware attack publicly.

Neither Roche company nor VIVENDA SPA company has reported experiencing a data breach publicly.

Neither Roche company nor VIVENDA SPA company has reported experiencing targeted cyberattacks publicly.

Neither VIVENDA SPA company nor Roche company has reported experiencing or disclosing vulnerabilities publicly.

Roche company has more subsidiaries worldwide compared to VIVENDA SPA company.

Roche company employs more people globally than VIVENDA SPA company, reflecting its scale as a Biotechnology Research.

Latest Global CVEs (Not Company-Specific)

Description

Formbricks is an open source qualtrics alternative. Prior to version 4.0.1, Formbricks is missing JWT signature verification. This vulnerability stems from a token validation routine that only decodes JWTs (jwt.decode) without verifying their signatures. Both the email verification token login path and the password reset server action use the same validator, which does not check the tokenโ€™s signature, expiration, issuer, or audience. If an attacker learns the victimโ€™s actual user.id, they can craft an arbitrary JWT with an alg: "none" header and use it to authenticate and reset the victimโ€™s password. This issue has been patched in version 4.0.1.

Risk Information
cvss3
Base: 9.4
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:H/I:H/A:L
Description

Apollo Studio Embeddable Explorer & Embeddable Sandbox are website embeddable software solutions from Apollo GraphQL. Prior to Apollo Sandbox version 2.7.2 and Apollo Explorer version 3.7.3, a cross-site request forgery (CSRF) vulnerability was identified. The vulnerability arises from missing origin validation in the client-side code that handles window.postMessage events. A malicious website can send forged messages to the embedding page, causing the victimโ€™s browser to execute arbitrary GraphQL queries or mutations against their GraphQL server while authenticated with the victimโ€™s cookies. This issue has been patched in Apollo Sandbox version 2.7.2 and Apollo Explorer version 3.7.3.

Risk Information
cvss3
Base: 8.2
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:R/S:C/C:L/I:H/A:N
Description

A security vulnerability has been detected in Portabilis i-Educar up to 2.10. Affected by this vulnerability is an unknown functionality of the file /consulta-dispensas. Such manipulation leads to improper authorization. The attack may be launched remotely. The exploit has been disclosed publicly and may be used.

Risk Information
cvss2
Base: 6.5
Severity: LOW
AV:N/AC:L/Au:S/C:P/I:P/A:P
cvss3
Base: 6.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L
cvss4
Base: 5.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A weakness has been identified in Portabilis i-Educar up to 2.10. Affected is an unknown function of the file /module/Api/aluno. This manipulation of the argument aluno_id causes improper authorization. The attack may be initiated remotely. The exploit has been made available to the public and could be exploited.

Risk Information
cvss2
Base: 6.5
Severity: LOW
AV:N/AC:L/Au:S/C:P/I:P/A:P
cvss3
Base: 6.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:L/UI:N/S:U/C:L/I:L/A:L
cvss4
Base: 5.3
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:L/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X
Description

A security flaw has been discovered in Tencent WeKnora 0.1.0. This impacts the function testEmbeddingModel of the file /api/v1/initialization/embedding/test. The manipulation of the argument baseUrl results in server-side request forgery. The attack can be launched remotely. The exploit has been released to the public and may be exploited. It is advisable to upgrade the affected component. The vendor responds: "We have confirmed that the issue mentioned in the report does not exist in the latest releases".

Risk Information
cvss2
Base: 7.5
Severity: LOW
AV:N/AC:L/Au:N/C:P/I:P/A:P
cvss3
Base: 7.3
Severity: LOW
CVSS:3.1/AV:N/AC:L/PR:N/UI:N/S:U/C:L/I:L/A:L
cvss4
Base: 6.9
Severity: LOW
CVSS:4.0/AV:N/AC:L/AT:N/PR:N/UI:N/VC:L/VI:L/VA:L/SC:N/SI:N/SA:N/E:P/CR:X/IR:X/AR:X/MAV:X/MAC:X/MAT:X/MPR:X/MUI:X/MVC:X/MVI:X/MVA:X/MSC:X/MSI:X/MSA:X/S:X/AU:X/R:X/V:X/RE:X/U:X